Ciclopirox Olamine Market
Ciclopirox Olamine Market Size, Share & Trends Analysis Report by Formulation Type (Topical Solutions, Suspensions, Creams, Lotions, Gels), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies, Direct Sales), and By Infection Type (Superficial Infections, Systemic Infections, Mixed Infections), By Application (Dermatological Disorders, Fungal Infections, Psoriasis, Dermatitis, Ophthalmic Applications, Oral Infections), and By End-User (Hospitals, Clinics, Home Care Settings, Pharmacies), Forecast Period (2025-2035)
Industry Overview
Ciclopirox olamine market size is estimated to reach $280 million in 2035 from $145 million in 2024 and is projected to grow at a CAGR of 6.4% during the forecast period (2025–2035). Ciclopirox Olamine, a broad-spectrum antifungal agent, is widely used to treat fungal infections (e.g., athlete’s foot, ringworm) and inflammatory dermatological conditions like psoriasis and dermatitis. The rising frequency of fungal infections is increasing demand for over-the-counter (OTC) antifungal products, and advancements in topical formulations are further supporting the market growth.
Market Dynamics
Increasing incidence of Dermatological Disorders
The increasing global cases of fungal infections represent a significant driver for the Ciclopirox Olamine market. Factors such as growing immunocompromised patient populations, rising diabetes cases, and changing lifestyles have contributed to higher incidence rates of various fungal conditions, such as ringworm, athlete's foot, tinea, and candidiasis. Other factors that affect dermatophytosis include climate factors, migration, and personal aspects, including immunological status. According to surveys conducted by the World Health Organization, it has been found that approximately 25% of the global population is impacted by dermatophytes. Additionally, as per the National Library of Medicine, Dermatophytosis, a frequently occurring superficial infection, exhibits a worldwide distribution, with a higher incidence in tropical and subtropical areas, attributed to the elevated levels of temperature and humidity. Dermatophytosis is believed to impact around 20–25% of the global population.
Ciclopirox Olamine Market Share by Formulation Type, 2024
Growing Demand for Effective Over-the-Counter Solutions
Simultaneously, consumer preference for accessible, effective, and convenient treatment options has propelled the demand for over-the-counter (OTC) ciclopirox olamine formulations. Busy lifestyles and increasing healthcare costs have led patients to seek self-medication options for common fungal conditions. Also, Pharmaceutical companies have responded by developing user-friendly formulations suitable for home application, including creams, lotions, and topical solutions. The rising availability of these products through retail and online pharmacies has significantly contributed to market expansion, particularly in regions with limited healthcare infrastructure.
Market Segmentation
- Based on the formulation type, the market is segmented into (topical solutions, suspensions, creams, lotions, and gels)
- Based on the distribution channel, the market is segmented into (online pharmacies, retail pharmacies, hospital pharmacies, and direct sales)
- Based on the Infection Type, the market is segmented into (superficial infections, Systemic infections, mixed infections)
- Based on the application, the market is segmented into (dermatological disorders, fungal infections, psoriasis, dermatitis, ophthalmic applications, and oral infections)
Formulation Type Segment to Dominate the Market
The growing adoption rate for formulation types of solutions for dermatophytosis, such as Topical Solutions, Suspensions, Creams, Lotions, and Gels. Among these, Creams currently keep the largest market share, approximately 35%, owing to their ease of application, the superior absorption rate in skin, and more consumer preference. Topical Solutions follow closely at 28% market share, valued for their precision in treating localized infections, and gels are expected to witness the fastest growth during the forecast period due to their non-greasy texture and rapid absorption.
Distribution Channel Segment to Witness Fastest Growth
Distribution channels for Ciclopirox Olamine include online pharmacies, retail pharmacies, hospital pharmacies, and direct sales. Among these channels, retail pharmacies are dominant with approximately 45% market share, benefiting from their widespread accessibility, easy availability, and consumer trust. Furthermore, online pharmacies are expecting the fastest growth rate, anticipated at 12% annually during the forecast period, increasing digitalization, convenience factors, and expanded product availability through e-commerce platforms such as TATA mg, Netmed, etc., to further support this market.
Regional Outlook
The global ciclopirox olamine is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Asia-Pacific to Witness Fastest Growth for Ciclopirox Olamine Market
The Asia-Pacific region is expected to exhibit the highest growth rate during the forecast period. Pivotal Factors such as large patient populations, increasing healthcare expenditure, rising awareness about skin health, and expanding access to medical care significantly propel this market. Moreover, China, Japan, and India contribute to the largest markets, also with domestic manufacturers are contributing to product availability and market competitiveness.
Market Players Outlook
The major companies operating in the global ciclopirox olamine market include Bausch Health (Penlac), Glenmark Pharmaceuticals Ltd., Sanofi SA, Perrigo Company plc, and Teva Pharmaceuticals USA, Inc., among others. Market players leverage partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In January 2024, Taro Pharmaceutical Industries Ltd announced that it entered into a definitive merger agreement with Sun Pharmaceutical. The combined entity will firmly move forward, leveraging its global strengths and capabilities to better serve the needs of patients and healthcare professionals.
The Report Covers
- Market value data analysis of 2024 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global ciclopirox olamine market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Global Ciclopirox Olamine Market Sales Analysis – Formulation | Distribution Channel | Infection Type | Application | End-User ($ Million)
• Ciclopirox Olamine Market Sales Performance of Top Countries
1.1. Research Methodology
• Primary Research Approach
• Secondary Research Approach
1.2. Market Snapshot
2. Market Overview and Insights
2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Ciclopirox Olamine Trends
2.2.2. Market Recommendations
3. Market Determinants
3.1. Market Drivers
3.1.1. Drivers For Global Ciclopirox Olamine Market: Impact Analysis
3.2. Market Pain Points and Challenges
3.2.1. Restraints For Global Ciclopirox Olamine Market: Impact Analysis
3.3. Market Opportunities
4. Competitive Landscape
4.1. Competitive Dashboard – Ciclopirox Olamine Market Revenue and Share by Manufacturers
• Ciclopirox Olamine Product Comparison Analysis
• Top Market Player Ranking Matrix
4.2. Key Company Analysis
4.2.1. Bausch Health Companies Inc.
4.2.1.1. Overview
4.2.1.2. Product Portfolio
4.2.1.3. Financial Analysis (Subject to Data Availability)
4.2.1.4. SWOT Analysis
4.2.1.5. Business Strategy
4.2.2. Glenmark Pharmaceuticals Ltd.
4.2.2.1. Overview
4.2.2.2. Product Portfolio
4.2.2.3. Financial Analysis (Subject to Data Availability)
4.2.2.4. SWOT Analysis
4.2.2.5. Business Strategy
4.2.3. Perrigo Company plc
4.2.3.1. Overview
4.2.3.2. Product Portfolio
4.2.3.3. Financial Analysis (Subject to Data Availability)
4.2.3.4. SWOT Analysis
4.2.3.5. Business Strategy
4.2.4. Sanofi SA
4.2.4.1. Overview
4.2.4.2. Product Portfolio
4.2.4.3. Financial Analysis (Subject to Data Availability)
4.2.4.4. SWOT Analysis
4.2.4.5. Business Strategy
4.2.5. Teva Pharmaceuticals USA, Inc.
4.2.5.1. Overview
4.2.5.2. Product Portfolio
4.2.5.3. Financial Analysis (Subject to Data Availability)
4.2.5.4. SWOT Analysis
4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
4.3.1. Merger and Acquisition
4.3.2. Product Launch
4.3.3. Partnership And Collaboration
5. Global Ciclopirox Olamine Market Sales Analysis By Formulation Type ($ Million)
5.1. Topical Solutions
5.2. Suspensions
5.3. Others (Creams, Lotions, and Gel)
6. Global Ciclopirox Olamine Market Sales Analysis By Distribution Channel ($ Million)
6.1. Online Pharmacies
6.2. Retail Pharmacies
6.3. Hospital Pharmacies
6.4. Direct Sales
7. Global Ciclopirox Olamine Market Sales Analysis By Infection Type ($ Million)
7.1. Superficial Infections
7.2. Systemic Infections
7.3. Mixed Infections
8. Global Ciclopirox Olamine Market Sales Analysis By Application ($ Million)
8.1. Dermatological Disorders
8.2. Fungal Infections
8.3. Psoriasis
8.4. Dermatitis
8.5. Ophthalmic Applications
8.6. Oral Infections
9. Global Ciclopirox Olamine Market Sales Analysis By End-User ($ Million)
9.1. Hospitals
9.2. Clinics
9.3. Home Care Settings
9.4. Pharmacies
10. Regional Analysis
10.1. North American Ciclopirox Olamine Market Sales Analysis – Formulation | Distribution Channel | Infection Type | Application | End-User ($ Million)
• Macroeconomic Factors for North America
10.1.1. United States
10.1.2. Canada
10.2. European Ciclopirox Olamine Market Sales Analysis – Formulation | Distribution Channel | Infection Type | Application | End-User ($ Million)
• Macroeconomic Factors for Europe
10.2.1. UK
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. France
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Asia-Pacific Ciclopirox Olamine Market Sales Analysis – Formulation | Distribution Channel | Infection Type | Application | End-User ($ Million)
• Macroeconomic Factors for Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. South Korea
10.3.4. India
10.3.5. Australia & New Zealand
10.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
10.3.7. Rest of Asia-Pacific
10.4. Rest of the World Ciclopirox Olamine Market Sales Analysis – Formulation | Distribution Channel | Infection Type | Application | End-User ($ Million)
• Macroeconomic Factors for the Rest of the World
10.4.1. Latin America
10.4.2. Middle East and Africa
11. Company Profiles
11.1. Bausch Health (Penlac)
11.1.1. Quick Facts
11.1.2. Company Overview
11.1.3. Product Portfolio
11.1.4. Business Strategies
11.2. Brinton Pharmaceuticals Ltd.
11.2.1. Quick Facts
11.2.2. Company Overview
11.2.3. Product Portfolio
11.2.4. Business Strategies
11.3. Cipla Limited
11.3.1. Quick Facts
11.3.2. Company Overview
11.3.3. Product Portfolio
11.3.4. Business Strategies
11.4. Glenmark Pharmaceuticals Ltd.
11.4.1. Quick Facts
11.4.2. Company Overview
11.4.3. Product Portfolio
11.4.4. Business Strategies
11.5. Healing Pharma India Pvt. Ltd.
11.5.1. Quick Facts
11.5.2. Company Overview
11.5.3. Product Portfolio
11.5.4. Business Strategies
11.6. Intas Pharmaceuticals Ltd
11.6.1. Quick Facts
11.6.2. Company Overview
11.6.3. Product Portfolio
11.6.4. Business Strategies
11.7. Medimetriks Pharmaceuticals
11.7.1. Quick Facts
11.7.2. Company Overview
11.7.3. Product Portfolio
11.7.4. Business Strategies
11.8. Padagis US LLC
11.8.1. Quick Facts
11.8.2. Company Overview
11.8.3. Product Portfolio
11.8.4. Business Strategies
11.9. Perrigo Company plc
11.9.1. Quick Facts
11.9.2. Company Overview
11.9.3. Product Portfolio
11.9.4. Business Strategies
11.10. Seqens International SAS
11.10.1. Quick Facts
11.10.2. Company Overview
11.10.3. Product Portfolio
11.10.4. Business Strategies
11.11. Synmedic
11.11.1. Quick Facts
11.11.2. Company Overview
11.11.3. Product Portfolio
11.11.4. Business Strategies
11.12. Sun Pharmaceutical Industries Ltd
11.12.1. Quick Facts
11.12.2. Company Overview
11.12.3. Product Portfolio
11.12.4. Business Strategies
11.13. Teva Pharmaceuticals USA, Inc.
11.13.1. Quick Facts
11.13.2. Company Overview
11.13.3. Product Portfolio
11.13.4. Business Strategies
11.14. Taro Pharmaceuticals
11.14.1. Quick Facts
11.14.2. Company Overview
11.14.3. Product Portfolio
11.14.4. Business Strategies
1. Global Ciclopirox Olamine Market Research And Analysis By Formulation Type, 2024-2035, ($ Millions)
2. Global Ciclopirox Olamine Topical Solutions Market Research And Analysis By Region, 2024-2035 ($ Million)
3. Global Ciclopirox Olamine Suspensions Market Research And Analysis By Region, 2024-2035 ($ Million)
4. Global Other Formulation Ciclopirox Olamine Market Research And Analysis By Region, 2024-2035 ($ Million)
5. Global Ciclopirox Olamine Market Research And Analysis By Distribution Channel, 2024-2035 ($ Million)
6. Global Ciclopirox Olamine Via Online Pharmacies Market Research And Analysis By Region, 2024-2035 ($ Million)
7. Global Ciclopirox Olamine Via Retail Pharmacies Market Research And Analysis By Region, 2024-2035 ($ Million)
8. Global Ciclopirox Olamine Via Hospital Pharmacies Market Research And Analysis By Region, 2024-2035 ($ Million)
9. Global Ciclopirox Olamine Via Direct Sales Market Research And Analysis By Region, 2024-2035 ($ Million)
10. Global Ciclopirox Olamine Market Research And Analysis By Infection Type, 2024-2035 ($ Million)
11. Global Ciclopirox Olamine For Superficial Infections Market Research And Analysis By Region, 2024-2035 ($ Million)
12. Global Ciclopirox Olamine For Systemic Infections Market Research And Analysis By Region, 2024-2035 ($ Million)
13. Global Ciclopirox Olamine For Mixed Infections Market Research And Analysis By Region, 2024-2035 ($ Million)
14. Global Ciclopirox Olamine Market Research And Analysis By Application, 2024-2035 ($ Million)
15. Global Ciclopirox Olamine For Dermatological Disorders Market Research And Analysis By Region, 2024-2035 ($ Million)
16. Global Ciclopirox Olamine For Fungal Infections Market Research And Analysis By Region, 2024-2035 ($ Million)
17. Global Ciclopirox Olamine For Psoriasis Market Research And Analysis By Region, 2024-2035 ($ Million)
18. Global Ciclopirox Olamine For Dermatitis Market Research And Analysis By Region, 2024-2035 ($ Million)
19. Global Ciclopirox Olamine For Ophthalmic Applications Market Research And Analysis By Region, 2024-2035 ($ Million)
20. Global Ciclopirox Olamine For Oral Infections Market Research And Analysis By Region, 2024-2035 ($ Million)
21. Global Ciclopirox Olamine Market Research And Analysis By End-User, 2024-2035 ($ Million)
22. Global Ciclopirox Olamine For Hospitals Market Research And Analysis By Region, 2024-2035 ($ Million)
23. Global Ciclopirox Olamine For Clinics Market Research And Analysis By Region, 2024-2035 ($ Million)
24. Global Ciclopirox Olamine For Home Care Settings Market Research And Analysis By Region, 2024-2035 ($ Million)
25. Global Ciclopirox Olamine For Pharmacies Market Research And Analysis By Region, 2024-2035 ($ Million)
26. North American Ciclopirox Olamine Market Research And Analysis By Country, 2024-2035 ($ Million)
27. North American Ciclopirox Olamine Market Research And Analysis By Formulation Type, 2024-2035 ($ Million)
28. North American Ciclopirox Olamine Market Research And Analysis By Distribution Channel, 2024-2035 ($ Million)
29. North American Ciclopirox Olamine Market Research and Analysis By Infection Type, 2024-2035 ($ Million)
30. North American Ciclopirox Olamine Market Research and Analysis By Application, 2024-2035 ($ Million)
31. North American Ciclopirox Olamine Market Research and Analysis By End-User, 2024-2035 ($ Million)
32. European Ciclopirox Olamine Market Research And Analysis By Country, 2024-2035 ($ Million)
33. European Ciclopirox Olamine Market Research And Analysis By Formulation Type, 2024-2035 ($ Million)
34. European Ciclopirox Olamine Market Research And Analysis By Distribution Channel, 2024-2035 ($ Million)
35. European Ciclopirox Olamine Market Research And Analysis By Infection Type, 2024-2035 ($ Million)
36. European Ciclopirox Olamine Market Research And Analysis By Application, 2024-2035 ($ Million)
37. European Ciclopirox Olamine Market Research And Analysis By End-User, 2024-2035 ($ Million)
38. Asia-Pacific Ciclopirox Olamine Market Research And Analysis By Country, 2024-2035 ($ Million)
39. Asia-Pacific Ciclopirox Olamine Market Research and Analysis By Formulation Type, 2024-2035 ($ Million)
40. Asia-Pacific Ciclopirox Olamine Market Research and Analysis By Distribution Channel, 2024-2035 ($ Million)
41. Asia-Pacific Ciclopirox Olamine Market Research and Analysis By Infection Type, 2024-2035 ($ Million)
42. Asia-Pacific Ciclopirox Olamine Market Research and Analysis By Application, 2024-2035 ($ Million)
43. Asia-Pacific Ciclopirox Olamine Market Research and Analysis By End-User, 2024-2035 ($ Million)
44. Rest Of The World Ciclopirox Olamine Market Research And Analysis By Country, 2024-2035 ($ Million)
45. Rest Of The World Ciclopirox Olamine Market Research And Analysis By Formulation Type, 2024-2035 ($ Million)
46. Rest Of The World Ciclopirox Olamine Market Research And Analysis By Distribution Channel, 2024-2035 ($ Million)
47. Rest Of The World Ciclopirox Olamine Market Research And Analysis By Infection Type, 2024-2035 ($ Million)
48. Rest Of The World Ciclopirox Olamine Market Research And Analysis By Application, 2024-2035 ($ Million)
49. Rest Of The World Ciclopirox Olamine Market Research And Analysis By End-User, 2024-2035 ($ Million)
1. Global Ciclopirox Olamine Market Share By Formulation Type, 2024 Vs 2035 (%)
2. Global Ciclopirox Olamine Topical Solutions Market Share By Region, 2024 Vs 2035 (%)
3. Global Ciclopirox Olamine Suspensions Market Share By Region, 2024 Vs 2035 (%)
4. Global Other Formulation Ciclopirox Olamine Market Share By Region, 2024 Vs 2035 (%)
5. Global Ciclopirox Olamine Market Share By Distribution Channel, 2024 Vs 2035 (%)
6. Global Ciclopirox Olamine Via Online Pharmacies Market Share By Region, 2024 Vs 2035 (%)
7. Global Ciclopirox Olamine Via Retail Pharmacies Market Share By Region, 2024 Vs 2035 (%)
8. Global Ciclopirox Olamine Via Hospital Pharmacies Market Share By Region, 2024 Vs 2035 (%)
9. Global Ciclopirox Olamine Via Direct Sales Market Share By Region, 2024 Vs 2035 (%)
10. Global Ciclopirox Olamine Market Share By Infection Type, 2024 Vs 2035 (%)
11. Global Ciclopirox Olamine For Superficial Infections Market Share By Region, 2024 Vs 2035 (%)
12. Global Ciclopirox Olamine For Systemic Infections Market Share By Region, 2024 Vs 2035 (%)
13. Global Ciclopirox Olamine For Mixed Infections Market Share By Region, 2024 Vs 2035 (%)
14. Global Ciclopirox Olamine Market Share By Application, 2024 Vs 2035 (%)
15. Global Ciclopirox Olamine For Dermatological Disorders Market Share By Region, 2024 Vs 2035 (%)
16. Global Ciclopirox Olamine For Fungal Infections Market Share By Region, 2024 Vs 2035 (%)
17. Global Ciclopirox Olamine For Psoriasis Market Share By Region, 2024 Vs 2035 (%)
18. Global Ciclopirox Olamine For Dermatitis Market Share By Region, 2024 Vs 2035 (%)
19. Global Ciclopirox Olamine For Ophthalmic Applications Market Share By Region, 2024 Vs 2035 (%)
20. Global Ciclopirox Olamine For Oral Infections Market Share By Region, 2024 Vs 2035 (%)
21. Global Ciclopirox Olamine Market Share By End-User, 2024 Vs 2035 (%)
22. Global Ciclopirox Olamine For Hospitals Market Share By Region, 2024 Vs 2035 (%)
23. Global Ciclopirox Olamine For Clinics Market Share By Region, 2024 Vs 2035 (%)
24. Global Ciclopirox Olamine For Home Care Settings Market Share By Region, 2024 Vs 2035 (%)
25. Global Ciclopirox Olamine For Pharmacies Market Share By Region, 2024 Vs 2035 (%)
26. Global Ciclopirox Olamine Market Share By Country, 2024 Vs 2035 (%)
27. US Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
28. Canada Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
29. UK Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
30. France Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
31. Germany Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
32. Italy Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
33. Spain Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
34. Russia Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
35. Rest Of Europe Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
36. India Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
37. China Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
38. Japan Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
39. Australia And New Zealand Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
40. ASEAN Economies Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
41. Rest Of Asia-Pacific Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
42. Latin America Ciclopirox Olamine Market Size, 2024-2035 ($ Million)
43. Middle East And Africa Ciclopirox Olamine Product Market Size, 2024-2035 ($ Million)
FAQS
The size of the Ciclopirox Olamine market in 2024 is estimated to be around $145 million.
Asia Pacific holds the largest share in the Ciclopirox Olamine market.
Leading players in the Ciclopirox Olamine market include Bausch Health (Penlac), Glenmark Pharmaceuticals Ltd., Sanofi SA, Perrigo Company plc, and Teva Pharmaceuticals USA, Inc., among others.
Ciclopirox Olamine market is expected to grow at a CAGR of 6.4% from 2025 to 2035.
The Ciclopirox Olamine Market is growing due to the rising prevalence of fungal infections and increasing demand for effective topical antifungal treatments.